Haemonetics Corp (HAE) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2026, Haemonetics reported revenue of $1.33B, down 2.0% from $1.36B the year before. Net income was $97.3M (a 7.3% net margin), or $2.05 per diluted share. Gross margin was 59.0% and operating margin was 11.7%. Operating activities generated $293.2M of cash, leaving $260.4M of free cash flow. At fiscal year end, Haemonetics held $2.40B in total assets against $1.60B in total liabilities, including $245.4M of cash and equivalents.
Open the full interactive Haemonetics financials → Quarterly statements, key ratios, valuation history and price charts.
Haemonetics Key Stats
| Share Price | $121.72 |
|---|---|
| Market Cap | $5.56B |
| P/E Ratio | 59.4 |
| Revenue YoY Growth | -2.0% |
| 52-Week Range | $48.58 – $122.06 |
| Shares Outstanding | 45.4 million (basic, 2027 Q1) |
Haemonetics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $870.5M | $993.2M | $1.17B | $1.31B | $1.36B | $1.33B |
| Cost of Goods Sold | $472.6M | $487.7M | $553.6M | $617.5M | $611.9M | $546.4M |
| Gross Profit | $397.8M | $505.5M | $615.1M | $691.5M | $749.0M | $787.6M |
| Operating Income | $89.7M | $80.8M | $156.0M | $164.9M | $221.8M | $156.7M |
| Pre-Tax Income | $72.9M | $63.6M | $141.4M | $151.9M | $212.1M | $128.0M |
| Income Tax | -$6.6M | $20.3M | $26.0M | $34.3M | $44.4M | $30.7M |
| Net Income | $79.5M | $43.4M | $115.4M | $117.6M | $167.7M | $97.3M |
| Diluted EPS | $1.55 | $0.84 | $2.24 | $2.29 | $3.31 | $2.05 |
Haemonetics Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $327.3M | $339.0M | $346.4M | $339.4M |
| Net Income | $38.7M | $44.7M | -$20.1M | $33.0M |
| Diluted EPS | $0.81 | $0.95 | -$0.43 | $0.72 |
Haemonetics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $192.3M | $259.5M | $284.5M | $178.8M | $306.8M | $245.4M |
| Current Assets | $693.5M | $756.0M | $769.7M | $768.9M | $935.0M | $834.9M |
| Total Assets | $1.82B | $1.86B | $1.93B | $2.20B | $2.45B | $2.40B |
| Current Liabilities | $253.5M | $442.3M | $251.8M | $300.4M | $578.1M | $282.6M |
| Total Long-Term Debt | $707.6M | $773.6M | $765.9M | $807.8M | $1.22B | $1.22B |
| Total Liabilities | $1.09B | $1.11B | $1.12B | $1.24B | $1.63B | $1.60B |
| Shareholders' Equity | $731.7M | $749.4M | $818.0M | $960.0M | $820.8M | $796.3M |
Haemonetics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $108.8M | $172.3M | $273.1M | $181.8M | $181.7M | $293.2M |
| Cash From Investing | -$425.4M | -$86.3M | -$143.8M | -$322.4M | -$161.9M | -$179.5M |
| Cash From Financing | $367.5M | -$15.7M | -$100.4M | $38.2M | $108.8M | -$178.5M |
| Free Cash Flow | $71.8M | $75.8M | $162.9M | $115.5M | $142.4M | $260.4M |
Figures from Haemonetics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Haemonetics financials page for every line item.
Haemonetics Company Profile
| Ticker | HAE |
|---|---|
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | April 3 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000313143 |
Frequently Asked Questions
What was Haemonetics' revenue in fiscal 2026?
Haemonetics (HAE) reported revenue of $1.33B for fiscal 2026.
What is Haemonetics' annual revenue history?
Haemonetics' annual revenue by fiscal year: 2021: $870.5M; 2022: $993.2M; 2023: $1.17B; 2024: $1.31B; 2025: $1.36B; 2026: $1.33B.
What was Haemonetics' net income in fiscal 2026?
Haemonetics reported net income of $97.3M for fiscal 2026.
What was Haemonetics' earnings per share (EPS) in fiscal 2026?
Haemonetics' diluted EPS was $2.05 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Haemonetics generate in fiscal 2026?
Haemonetics generated $260.4M of free cash flow in fiscal 2026.
What was Haemonetics' revenue last quarter?
In its most recent reported quarter (2027 Q1), Haemonetics reported revenue of $339.4M.
How much debt does Haemonetics have?
Haemonetics reported $1.22B of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Haemonetics are outstanding?
Haemonetics reported a weighted average of 45.4 million basic shares outstanding in 2027 Q1.
What is Haemonetics' market cap?
Based on its latest closing price, Haemonetics (HAE) has a market capitalization of about $5.56B.
When does Haemonetics' fiscal year end?
Haemonetics' fiscal year end, as registered with the SEC, is April 3.
Where is Haemonetics headquartered?
Haemonetics lists its business address in Boston, Massachusetts in its SEC filings.